Stock Details
GILD is Gilead Sciences, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 62.03$. Average daily volumn in 3 months 8.29M. Market cap 79.12B



Stock symbol : GILD. Exchange : NasdaqGS. Currency : USD
Lastest price : 63.08$. Total volume : 9.21M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Gilead Sciences, Inc. (GILD)
Last Price
63.08$
Change
0.50
Volume
9.21M

Previous Close62.58
Open62.81
Day Range61.85-63.13
Bid62.71 x 40k
Ask63.23 x 1.8k
Volume9.21M
Average Volume8.29M
Market Cap79.12B
Beta0.38
52 Week Range57.17-74.12
Trailing P/E17.62
Foward P/E9.98
Dividend (Yield %)4.63%
Ex-Dividend Date2022-06-14



Financial Details


According to Gilead Sciences, Inc.'s financial reports the company's revenue in 2021 were 27.3B an increase( +12.5%) over the years 2020 revenue that were of 24.69B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 123M( +4778.05%).


Loading ...



Organization

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li... ver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Cap:
79.12B
Revenue:
27.3B
Total Assets:
67.95B
Total Cash:
5.34B



News about "Gilead Sciences, Inc."

carnegie-capital-asset-management-llc-cuts-holdings-in-gilead-sciences-inc-nasdaqgild-image

Carnegie Capital Asset Management LLC Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Source from : ETF Daily News - 1 days ago

Carnegie Capital Asset Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 5.1% in the first quarter, according to the company in its most recent ...See details»


carnegie-capital-asset-management-llc-has-358000-position-in-gilead-sciences-inc-nasdaqgild-image

Carnegie Capital Asset Management LLC Has $358,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Source from : Defense World - 1 days ago

Carnegie Capital Asset Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 5.1% in the first quarter, HoldingsChannel.com reports. The fund owned 6,025 shares ...See details»


gilead-sciences-inc-nasdaqgild-shares-sold-by-massmutual-trust-co-fsb-adv-image

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Massmutual Trust Co. FSB ADV

Source from : Defense World - 2 days ago

Massmutual Trust Co. FSB ADV lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 41.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & ...See details»


gilead-sciences-inc-nasdaqgild-shares-sold-by-mcia-inc-image

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by MCIA Inc

Source from : ETF Daily News - 3 days ago

MCIA Inc trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) by 7.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 24,153 shares of ...See details»


gilead-gild-announces-positive-data-on-hepcludex-for-hdv-image

Gilead (GILD) Announces Positive Data on Hepcludex for HDV

Source from : YAHOO!Finance - 1 days ago

Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.See details»


gilead-week-48-findings-underscore-efficacy-of-bulevirtide-for-treatment-of-chronic-hdv-image

Gilead: Week 48 Findings Underscore Efficacy Of Bulevirtide For Treatment Of Chronic HDV

Source from : Nasdaq - 2 days ago

(GILD) reported week 48 results from the phase 3 trial evaluating Hepcludex or bulevirtide for the treatment of chronic hepatitis delta virus infection. The company said these data reinforce the ...See details»


gilead-chmp-adopts-positive-opinion-for-lenacapavir-to-treat-people-with-multi-drug-resistant-hiv-image

Gilead: CHMP Adopts Positive Opinion For Lenacapavir To Treat People With Multi-Drug Resistant HIV

Source from : Nasdaq - 2 days ago

(GILD) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in ...See details»


gilead-sciences-inc-gild-is-offering-a-buy-in-opportunity-image

Gilead Sciences Inc. (GILD) is offering a Buy-In Opportunity

Source from : investchronicle - 12 days ago

Letโ€™s start up with the current stock price of Gilead Sciences Inc. (GILD), which is $59.15 to be very precise. The Stock rose vividly during the last session to $60.43 after opening rate of $60.06 ...See details»


Gilead Gets CHMP Backing for Lenacapavir in Multi-Drug Resistant HIV >GILD

Source from : MarketWatch - 1 days ago

By Colin Kellaher Gilead Sciences Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval ...See details»


Gilead Reports Positive Results from Hepatitis Drug Trial

Source from : MarketWatch - 2 days ago

Gilead Sciences Inc. said Thursday that the latest clinical trial evaluating the antiviral medication Hepcludex for the treatment of chronic hepatitis delta virus showed significant viral declines at ...See details»


gilead-sciences-shares-cross-5-yield-mark-image

Gilead Sciences Shares Cross 5% Yield Mark

Source from : Forbes - 11 days ago

In trading on Tuesday, shares of Gilead Sciences were yielding above the 5% mark based on its quarterly dividend (annualized to $2.92), with the stock changing hands as low as $57.16 on the day.See details»


Traders See Bumpy Road Ahead For Gilead Sciences

Source from : Benzinga.com - 2 days ago

Gilead Sciences, Inc. GILD climbed on Wednesday, even as the S&P 500 ended the day with losses. On CNBC's "Options Action," Tony Zhang said that Gilead Sciences traded nearly 2.5 times its average ...See details»


gilead-to-present-latest-data-from-across-liver-disease-development-programs-at-the-international-liver-congress-2022-image

Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congressโ„ข 2022

Source from : YAHOO!Finance - 4 days ago

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that more than 80 abstracts will be presented at the International Liver Congressโ„ข (ILC) 2022, taking place from June 22-26, 2022. Key oral ...See details»


Gilead Sciences, Inc. (GILD) CEO Dan O'Day Presents at Goldman Sachs Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 10 days ago

Goldman Sachs Global Healthcare Conference June 15, 2022 02:20 PM ET Company Participants Dan O'Day - Chairman & Chief Executive ...See details»